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Abstract
Tumor development requires angiogenesis and anti-angiogenic therapies have been introduced in the treatment of cancer.
In this context, heparan sulfate proteoglycans (HSPGs) emerge as interesting targets, owing to their function as co-receptors
of major, pro-angiogenic factors. Accordingly, previous studies have suggested anti-tumor effects of heparin, i.e. over-
sulfated HS, and various heparin mimetics; however, a significant drawback is their unspecific mechanism of action and
potentially serious side-effects related to their anticoagulant properties. Here, we have explored the use of human ScFv anti-
HS antibodies (aHS) as a more rational approach to target HSPG function in endothelial cells (ECs). aHS were initially
selected for their recognition of HS epitopes localized preferentially to the vasculature of patient glioblastoma tumors, i.e.
highly angiogenic brain tumors. Unexpectedly, we found that these aHS exhibited potent pro-angiogenic effects in primary
human ECs. aHS were shown to stimulate EC differentiation, which was associated with increased EC tube formation and
proliferation. Moreover, aHS supported EC survival under hypoxia and starvation, i.e. conditions typical of the tumor
microenvironment. Importantly, aHS-mediated proliferation was efficiently counter-acted by heparin and was absent in
HSPG-deficient mutant cells, confirming HS-specific effects. On a mechanistic level, binding of aHS to HSPGs of ECs as well
as glioblastoma cells was found to trigger p38 MAPK-dependent signaling resulting in increased proliferation. We conclude
that several aHS that recognize HS epitopes abundant in the tumor vasculature may elicit a pro-angiogenic response, which
has implications for the development of antibody-based targeting of HSPGs in cancer.
Citation: Christianson HC, van Kuppevelt TH, Belting M (2012) ScFv Anti-Heparan Sulfate Antibodies Unexpectedly Activate Endothelial and Cancer Cells through
p38 MAPK: Implications for Antibody-Based Targeting of Heparan Sulfate Proteoglycans in Cancer. PLoS ONE 7(11): e49092. doi:10.1371/journal.pone.0049092
Editor: Ramani Ramchandran, Medical College of Wisconsin, United States of America
Received August 21, 2012; Accepted October 8, 2012; Published November 9, 2012
Copyright:  2012 Christianson et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the Swedish Cancer Fund; the Swedish Research Council; the Swedish Society of Medicine; the Physiographic
Society, Lund; the Gunnar Nilsson, Lundgren and Kamprad Foundations; the Ska˚ne University Hospital donation funds; and the Governmental funding of clinical
research within the national health services (ALF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Mattias.Belting@med.lu.se
Introduction
The progression from malignant transformation into manifest
tumor development requires the recruitment of blood vessels, i.e.
the angiogenic switch [1,2]. Angiogenesis is a multi-step process
dependent on endothelial (EC) proliferation, migration into the
surrounding tissue and finally differentiation into a new vessel.
Binding of several angiogenic factors, e.g. VEGF-A, FGF, and HB-
EGF to heparan sulfate (HS) polysaccharide chains underlines the
importance of HS proteoglycans (PGs) in EC biology [3–5].
HSPGs act as co-receptors that present growth factors to their
high-affinity tyrosine kinase signaling receptors at the cell surface
[6,7]. Extensive postsynthetic modifications of the linear HS
chains, composed of repetitive N-acetylglucosamine and glucuro-
nic acid disaccharide units, include sulfation at various positions
along the chain, which results in negatively charged domains that
provide binding sites for various growth factors, proteases and
cytokines involved in tumor development [3–7]. Accordingly,
mouse embryos engineered to express a VEGF-A lacking the HS-
binding sequence exhibited a decrease in capillary branch
formation [8], and transgenic mouse models with either a
homozygous deletion of the HS-binding motif in PDGF-BB or
reduced HS sulfation, displayed defective pericyte recruitment and
obscured microvascular anatomy [9,10]. Altered expression of
regulatory enzymes involved in shaping the fine structure of HS
chains have been implicated in cancer, e.g. gene hypermethylation
mediated gene silencing of 3-O sulfotransferase and HSulf-1 was
found in several cancers [11], and HSulf-2 over expression
correlated with increased angiogenesis and growth factor binding
capacity in breast cancer [12]. Further, HS-degrading heparanase
has been associated with tumor progression and poor patient
outcome through remodeling of the tumor microenvironment
[13]. HSPGs have thus been implicated in several aspects of tumor
development and angiogenesis; however, the role of HSPG as a
target of anti-angiogenesis treatment remains to be defined. In
fact, several strategies have been explored in order to achieve this
purpose, most importantly the HS mimic heparin and its
derivatives [14–18]. Major drawbacks with these compounds are
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their relative unspecific modes of targeting, and significant risks of
bleeding complications associated with their anticoagulant activ-
ities. Other possible HS-targeted treatments for cancer therapy
involve proteins or peptides with positively charged amino acid
residues that act as competitive inhibitors of growth factor binding
to HS chains [19].
Antibody-based therapy is one of the fastest growing therapy
areas in medical oncology and antibodies targeting VEGF, the
epidermal growth factor receptor 2 (HER-2), EGF receptor or
CD20 have been approved in the treatment of e.g. metastatic
breast and colorectal cancer and aggressive B-cell lymphomas
[20]. Smaller recombinant antibodies like single-chain variable
fragment (ScFv) antibodies are interesting options of improved
targeting due to their favorable pharmacokinetics [21–23].
Interestingly, van Kuppevelt and co-workers have previously
described the development and characterization of several epitope
specific, phage display derived, ScFv aHS to probe the structural
diversity of HS chains in various tissues [24,25]. In the present
study, we sought to identify ScFv aHS that recognize HS epitopes
expressed in the vasculature of patient glioblastoma tumors, and
further investigated the use of these aHS as a putative strategy to
inhibit various aspects of EC function.
Results
Identification of aHS Clones that Recognize HS Epitopes
of the Tumor Vasculature
We initially sought to identify aHS clones with known epitope
specificities (Table 1) [26] that may recognize the vascular niche
of patient glioblastoma tumors. This tumor type was chosen based
on its well-known phenotypic characteristics of hypoxia-induced
angiogenesis manifested by profound EC hyperplasia [27]. As
shown in Fig. 1A–D, three separate aHS clones (AO4B08,
EV3C3, and HS4E4) preferentially stained for HS epitopes
localized to the tumor vasculature, i.e. aHS showed strong co-
localization with the EC markers von Willebrand factor (vWF) and
integrin avb3, the latter being a known marker of activated
endothelium [28]. HS epitopes recognized by the same set of aHS
antibodies were found to be expressed also in primary human ECs
(HUVECs) (Fig. S1A–C). The specificity of aHS for HS in vitro
was shown by markedly reduced binding to ECs following
treatment with heparanase lyase that enzymatically degrades HS
(Fig. S1D). The specificity of aHS for HS was also true in vivo in
glioblastoma xenograft tumor sections, as heparanase treatment
resulted in a complete loss of aHS staining (Fig. 1E, right upper
panel). We next performed stainings with an antibody (3G10) that
is known to specifically recognize HSPG core protein with a
remaining HS stub following treatment with heparanase, but that
does not recognize either free HS chains or intact HSPG [29].
Untreated tumor sections showed no staining with 3G10 (Fig. 1E,
lower left panel), whereas tumor sections treated with heparanase
displayed substantial positivity for the 3G10 epitope predomi-
nantly localized to vessel-like structures that closely resembled the
aHS staining pattern (cf. Fig. 1E, lower right panel and upper left
panel). Together, these studies identify several aHS clones that
recognize HS epitopes associated with intact HSPGs abundant in
the vascular niche of glioblastoma tumors.
Functional Effects of aHS in Primary Human ECs
Based on the hypothesis that HSPGs are suitable targets for anti-
angiogenic treatment [3–10,13–18] we next performed a series of
functional studies with primary human ECs. Consistent with a role
of HSPGs in EC function, the HS mimetic heparin markedly
reduced EC proliferation in a dose-dependent manner (Fig. 2A).
The same was true for the low molecular weight heparin compound
tinzaparin (Fig. 2B), which is a widely used anticoagulant and
that is currently under investigation for its tumor inhibiting
effects in lung cancer patients (http://clinicaltrials.gov/ct2/show/
NCT00475098?term= tinzaparin+cancer&rank= 7).
A significant drawback with heparins is their unspecific
mechanism of action and potentially serious adverse effects. We
thus decided to explore the possibility of antibody-based targeting
of HS as a more specific and rational anti-angiogenic strategy,
initially studying one of the previously selected aHS, i.e. AO4B08,
on EC function. AO4B08 treated ECs displayed an elongated
morphology with an approximately 75% increase of mean cell-
length as compared with untreated cells (Fig. 2C). EC elongation
is known to be associated with a tube forming and sprouting EC
phenotype [30]. Accordingly, AO4B08 was found to promote tube
formation .2-fold as compared with control cells (Fig. 2D).
Moreover, aHS was found to substantially increase EC prolifer-
ation in a dose-dependent manner with a maximal stimulation of
approximately 3.5-fold as compared with control (Fig. 2E).
Notably, AO4B08 mediated stimulation of EC proliferation was
shown already at 3 h of treatment, suggesting a relatively rapid
response. The effect of AO4B08 on EC proliferation was sustained
after 24 h of AO4B08 treatment (Fig. S2). Stimulation of EC
proliferation by AO4B08 was further supported by an increased
fraction of cells in S-phase, and a corresponding reduction of G1-
phase in AO4B08 treated as compared with control cells (Fig. 2F).
aHS Protects Primary Human ECs from Hypoxia and
Starvation Associated Cell-death
As hypoxia and nutrient deficiency are characteristic features of
the tumor microenvironment [31], and as hypoxia has been shown
to modulate the cell-surface HS composition of ECs into an
increased growth factor binding capacity [32], we reasoned that
antibody-mediated blockage of HS may sensitize ECs in the
context of hypoxia and starvation. To this end, ECs were cultured
at hypoxia (1% O2) in the presence or the absence of AO4B08,
and assessed for apoptosis by analysis of cleaved caspases. Serum
starvation of hypoxic ECs induced caspase 3 and 7 activation in
ECs and, interestingly, caspase cleavage was efficiently counter-
acted by AO4B08 treatment (Fig. 3A). In further support of these
data, AO4B08 was shown to significantly increase the number of
viable ECs at hypoxic and serum-deficient conditions (Fig. 3B).
Altogether, the above data suggest that an aHS shown to
recognize tumor vasculature-resident HS structures may exert
pro-angiogenic effects in ECs.
aHS Mediated Cell Stimulation is Specific for HS but is
not HS Epitope or Cell Specific
We next investigated the specificity of the functional effects of
aHS. AO4B08 stimulation of EC proliferation appeared strictly
dependent on HS binding as indicated by efficient reversal by
heparin in a dose-dependent manner (Fig. 4A). Already at the
lowest heparin concentration used (10 mg/ml), approximately 75%
of AO4B08-dependent proliferation was inhibited, and at 100 mg/
ml the effect was completely abrogated (Fig. 4A). Importantly, we
further found that additional aHS clones shown to recognize
glioblastoma tumor vasculature, HS4E4 and EV3C3 (Fig. 1), also
stimulated EC proliferation, and that this effect was efficiently
counter-acted by heparin (Fig. 4C). It should be noted that in the
proliferation experiments shown in Fig. 2A, cells were treated
with heparin for 48 h, whereas in the aHS reversal experiments
cells were incubated with heparin only for 3 h (Fig. 4A and C).
Importantly, various variants of CS, i.e. a glycosaminoglycan
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Figure 1. Identification of aHS that preferentially recognize HS epitopes of tumor vasculature. A–D, Patient glioblastoma tumor sections
were stained for HS using the aHS antibodies AO4B08 (A and D), EV3C3 (B) or HS4E4 (C) (green) and for vWF (A–C, endothelial marker; red) or integrin
avb3 (D, marker of activated endothelium; red), and analyzed by fluorescence microscopy. Strong co-association between HS epitopes and tumor
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closely related to heparin, was unable to reverse the stimulatory
effect of aHS (Fig. 4B). Moreover, under these conditions,
heparin (10 mg/ml) efficiently inhibited aHS cell-surface binding
(Fig. S3B). Although, these results indicate that aHS-mediated
effects on EC proliferation are HS specific but not restricted to a
specific HS epitope, the stimulatory effect was most pronounced
for EV3C3 followed by AO4B08 and HS4E4 (Fig. 4C). These
results seemed to correlate with the cell-surface abundance of the
respective aHS epitope, i.e. ECs preferentially bound aHS in the
order EV3C3.AO4B08.HS4E4 (Fig. S3A). Further, the effect
of the various aHS clones appeared not to be directly linked to the
cellular distribution of their respective epitope, as AO4B08 and
HS4E4 stainings displayed a similar pattern along the cell
periphery, whereas EV3C3 showed a more diffuse staining with
increased density towards the perinuclear region (Fig. S1A–C).
The specificity of aHS and the dependence on HSPG for their
stimulatory effects were next investigated using wild-type (CHO-
K1) and mutant (pgsA-745) CHO cells, genetically deficient in
xylosyl transferase (XT). XT catalyses the first step in HSPG
assembly, i.e. the linkage of xylose to specific serine residues in the
PG core protein. PgsA cells express approximately 5% HSPG as
compared with wild-type cells [33]. Treatment of CHO-K1 cells
with AO4B08, EV3C3 as well as HS4E4 resulted in an almost 2-
fold increase in proliferation, showing that the stimulatory effects
of aHS were not restricted to HUVECs (Fig. 4D). This notion
was reinforced by the finding that aHS induced the proliferation
of human umbilical artery ECs (HUAEC), i.e. another source of
primary human ECs, as well as the human glioblastoma cell-line
U-87 MG in a dose-dependent manner and to the same extent as
in HUVECs (Fig. 4E and F). Importantly, HSPG-deficient
mutant cells were unresponsive to all of the studied aHS (Fig. 4D),
providing genetic evidence that aHS-mediated activation of cell
proliferation requires unperturbed HS function.
aHS Dependent Stimulation of Proliferation Involves p38
MAPK Signaling Activation
We next wanted to elucidate whether aHS induced cell
proliferation involved a specific signaling pathway. Using a
phosphorylation-specific receptor tyrosine kinase array, we found
that aHS treatment did not activate receptors of known HS-
binding growth factors, i.e. FGFs, PDGFs, and VEGFs, as
compared to untreated ECs (Fig. 5A). These results suggest that
the mechanism of aHS-mediated stimulation of ECs is not due a
direct mimicking effect of HS-binding ligands. Interestingly, using
a phosphorylation-specific kinase array, aHS treatment was found
to significantly induce phosphorylation of the p38 MAPK
(approximately 2.5-fold) as compared to untreated ECs (Fig. 5B).
The array data were confirmed by western blotting, showing time-
dependent and transient induction of p-p38 MAPK by aHS
(Fig. 5C). Moreover, phosphorylation of CREB, a known
downstream target of p38 MAPK [34], appeared to be increased
upon aHS treatment (by approximately 35% as compared with
control) (Fig. 5B). However, phosphorylation of another MAPK
widely implicated in proliferation signaling, extracellular signal
regulated kinase 1/2 (ERK1/2), was unaffected by aHS treatment
(Fig. 5B). The effect of aHS on p38 MAPK signaling activation
appeared to be a more general phenomenon, as a similar response
was found in microvascular ECs isolated from mouse lung
(Fig. 5D) [35] as well as in U-87 MG glioblastoma cells (Fig.
S4A).
Several growth factors, perhaps most importantly pro-angio-
genic FGF, VEGF, and PDGF have been found to trigger p38
MAPK activation in certain cell types [36]. We thus performed a
series of angiogenesis and tyrosine kinase receptor phosphorylation
antibody array experiments to elucidate whether cell stimulatory
effects and p38 MAPK activation by aHS may be secondary to the
induction of specific growth factors and their respective signaling
receptors. However, we were unable to find significant induction
by aHS either of these growth factors or their receptors (data not
shown). To directly study the functional importance of p38 MAPK
signalling in aHS-mediated proliferation, we employed the well-
established p38 MAPK inhibitor SB203580 [34,37]. Expectedly,
the inhibitor efficiently counter-acted p38 MAPK activation in
HUVECs (Fig. S4B), and reduced serum as well as aHS-
mediated activation of the p38 MAPK down-stream target CREB
(Fig. S4C). SB203580 was shown to inhibit basal p-CREB (Fig.
S4C) and proliferation in non-stimulated HUVECs (data not
shown), but not in mouse ECs and U-87 MG glioblastoma cells
(Fig. 5E and F), i.e. further studies were performed in the latter
cell types. Interestingly, aHS-induced proliferation of mouse ECs
(Fig. 5E) as well as glioblastoma cells (Fig. 5F) was efficiently
attenuated by p38 MAPK inhibition. Together, these data indicate
that binding of aHS to cell-surface HSPGs of ECs as well as
vasculature is indicated by merged images (A–D, right panels; yellow). Images shown are representative of three different tumors and at least five
sections per tumor, and were obtained at 206magnification. Scale bar, 50 mM. E, Upper panels: Specificity of aHS was assessed by AO4B08 staining
of U-87 MG glioblastoma xenograft tumor sections following either no treatment (Ctrl) or pre-treatment with Heparinase III lyase (HS lyase) to digest
HS. Lower panels: 3G10 antibody was used to detect HS stubs of HSPGs that remain after HS lyase digestion. Expecedly, 3G10 staining was not
detectable in untreated tumor sections with intact HS (Ctrl, left panel); however, 3G10 staining of HS lyase treated specimens (right panel) shows a
vessel like pattern that largely resembles the AO4B08 staining (upper left panel). Scale bar, 20 mM.
doi:10.1371/journal.pone.0049092.g001
Table 1. aHS used in this study and their epitope specificities.*
Clone VH DP CDR3 GAG
Modifications involved in
binding
Modifications that may inhibit
binding
AO4B08 3 47 SLRMNGWRAHQ HS NS, IdoA, 2-OS, 6-OS
HS4E4 3 38 HAPLRNTRTNT HS NAc, NS, IdoA 2-OS, 6-OS
EV3C3 3 42 GYRPRF HS NS, IdoA, 2-OS 6-OS
CDR3, amino acid sequence of the complementarity determining region 3 (a major determinant in antigen recognition); DP, gene number; GAG: class of
glycosaminoglycan with which the antibody reacts; IdoA, iduronic acid; NAc, N-acetylation; VH, heavy chain germ line family.
*Adapted from reference [26].
doi:10.1371/journal.pone.0049092.t001
Cell Activation by Anti-HS Antibodies via p38 MAPK
PLOS ONE | www.plosone.org 4 November 2012 | Volume 7 | Issue 11 | e49092
Cell Activation by Anti-HS Antibodies via p38 MAPK
PLOS ONE | www.plosone.org 5 November 2012 | Volume 7 | Issue 11 | e49092
glioblastoma cells triggers a p38 MAPK-dependent signaling
pathway resulting in increased proliferation.
Discussion
Antibody based tumor vascular targeting for the treatment of
cancer is based on the fact that tumors require angiogenesis in
order to expand and metastasize, and that ECs face the lumen of
blood vessels and thus are relatively accessible for systemic
therapy. The rationale of HSPG-directed anti-tumor therapy is
the possibility of simultaneous multi-targeting of some key pro-
angiogenic proteins, most importantly VEGF-A, FGFs, HB-EGF,
PDGF, and IL-8, which may promote tumor angiogenesis in a
partly redundant manner with implications for treatment resis-
tance. In the present study, we have identified several aHS clones
that recognize HS epitopes abundantly expressed in the vascula-
ture of malignant glioma tumors. Unexpectedly, we find that these
aHS stimulate several aspects of EC function, i.e. differentiation,
tube formation, proliferation and resistance to hypoxia and
starvation dependent cell-death. We provide evidence that these
effects are specifically dependent on aHS binding, and are not
related to unspecific interactions. Importantly, the stimulatory
effects appeared to involve several HS epitopes, as AO4B08,
EV3C3 as well as HS4E4 all displayed stimulatory activity, which
appeared to be directly correlated with their respective cell-surface
abundance in ECs. Furthermore, aHS-induced stimulation was
found in three different types of primary ECs, i.e. HUVECs,
HUAECs, and mouse lung microvascular ECs, as well as in
transformed CHO cells and human U-87 MG glioblastoma cells,
suggesting that our findings have more general relevance.
Previous studies lend support to the notion of HSPG as a
relevant target of cancer therapy [7–18]. These strategies have
mainly been focused on heparin, its derivatives, and other
polyanionic compounds, such as suramin [18]. Other strategies
to interfere with HSPG function include false substrates for HS
biosynthesis, i.e. xylosides [38], inhibition of HS-degrading
enzymes [39], and genetic manipulation of the HS biosynthetic
machinery [40]. The demonstrated inhibitory effects of these
compounds can mainly be explained by direct competitive
blockage of ligand-HSPG interactions thereby attenuating down-
stream receptor signaling activation (polyanionic compounds), or
by modulating the biological availability of HSPGs for ligand
binding (xylosides, enzymes, genetic strategies). Interestingly, our
data indicate that the dominant effect of antibody binding to
cellular HSPGs is to directly promote cell activation, rather than to
block HS ligand-dependent cell activation. On a mechanistic level,
binding of aHS to HSPGs of ECs as well as glioblastoma cells was
found to trigger p38 MAPK-dependent signaling, and unper-
turbed p38 MAPK function was required for aHS-mediated cell
stimulation. In this context, it is notable that other HS-binding
ligands have been shown to stimulate ECs through the p38 MAPK
pathway [41]. This intracellular kinase was initially identified as a
major pro-inflammatory mediator and was later found to be
involved in multiple cellular processes and in diseases including
cancer [36]. In fact, p38 MAPK has been implicated as a
suppressor of malignant processes, e.g. oncogene-mediated cell
senescence and contact inhibition. Other studies, however, have
shown pro-migratory and invasive effects of p38 MAPK activation
in cancer cells and stromal cells [36]. Like other MAPKs, the
functions of p38 are dependent on its down-stream kinases,
including serine/threonine kinases such as p38-regulated/activat-
ed kinase (PRAK) and MAPK-activated kinase-2, and many
different up-stream kinases, such as MKK3/6, MKK4, as well as
MAPKK independent signals. Cell specific as well as subcellular
localization specific effects add to the complexity of p38 function.
In the context of tumor angiogenesis it is of particular interest that
p38 was recently shown to activate tumor ECs through PRAK
[42]. Future studies will have to clarify whether PRAK and what
alternative p38 down-stream signaling mechanisms are involved in
aHS-mediated pro-angiogenic effects. Moreover, our studies were
limited to the kinases detected by the antibody array, i.e. other
kinases not included in the array could be activated by aHS in
addition to p38.
The dominating cell-surface HSPGs are the syndecan and
glypican families that have both been implicated in the regulation
of growth factor signaling and angiogenesis [6,7]. The syndecans
are transmembrane HSPGs that have a direct role in cell signaling
events, e.g. the cytoplasmic domain of syndecan-4 contains a
central region that binds phosphatidylinositol 4 5-bisphosphate,
which allows oligomerization of syndecan with subsequent binding
and activation of protein kinase C-alpha [43–44]. Syndecan-4 has
also been shown to promote the formation of actin stress fibers and
focal adhesions in conjunction with the integrins [45]. Interest-
ingly, glypican-1 was highly expressed in glioma vasculature, while
absent in normal brain ECs. Further, induced over-expression of
glypican-1 in normal ECs resulted in increased mitogenesis
[46,47]. The glypicans are linked to the cell surface via a lipid-
anchor, which localizes this type of HSPG to cholesterol-rich
membrane raft/caveolae domains [6]. Notably, recent studies
point at an important role of membrane-raft associated endocy-
tosis in signaling regulation [48], and previous studies from our
group have shown that HSPGs are endocytosed mainly through
this pathway [49]. It is thus tempting to speculate that aHS
binding induces clustering of glypicans at the cell-surface, which
results in raft assembly, endocytosis, p38 MAPK signaling
activation and the observed functional effects. However, our data
are not in favor of this idea, as HS4E4, EV3C3 as well as AO4B08
showed cell stimulatory activities, whereas only the latter has been
shown to exert internalizing capacity [50].
Figure 2. Potent pro-angiogenic effects of aHS in primary human ECs. A–B, HUVECs were grown in serum free medium in the presence of
the indicated concentrations of either heparin (A) or the low molecular weight heparin, Tinzaparin (B). Cell proliferation was determined by
measurement of incorporated [3H]thymidine over a period of 48 h. C, HUVECs were grown in serum free medium in the absence (Ctrl) or presence of
AO4B08 (aHS, 3 mg/ml) for 72 h. Cell morphology was visualized by crystal violet staining, and captured using an inverted light microscope equipped
with a digital camera. Left and mid panels show representative pictures of an elongated EC phenotype in aHS-treated as compared with control cells.
Right panel shows quantitative analysis of the length of individual cells in three separate microscopic fields per well (n = 4), using Image J software. D,
HUVECs were cultured on matrigel, i.e. a tumor-derived extracellular matrix, in serum free medium in the absence (Ctrl) or presence of AO4B08 (aHS;
3 mg/ml) and were allowed to form tubes for approximately 20 h. Left and mid panels show representative pictures of increased tube formation in
aHS-treated as compared with control cells from at least three independent experiments. Right panel shows quantitative analysis of the number of
intact tubes from three microscopic fields per well (n = 4) using Image J software. E and F, aHS stimulates EC proliferation: HUVECs were grown in
serum free medium in the absence or presence of AO4B08 (aHS) at the indicated concentrations and assessed for proliferation by [3H]thymidine
incorporation over a period of 3 h. F, HUVECs were subjected to cell cycle phase analysis after 6 h without (Ctrl) or with AO4B08 (aHS) treatment.
Fraction of cells in the respective cell cycle phase was determined by flow cytometry following nuclear staining with propidium iodide. Data are
presented as the average 6 S.D. * Statistically different from untreated Ctrl, P,0.05.
doi:10.1371/journal.pone.0049092.g002
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We conclude that several aHS clones that recognize HS
epitopes abundant in the tumor vasculature activate ECs as well as
transformed cells in vitro, which irrespective of the underlying
mechanism, may have important implications for the development
of antibody-based targeting of HSPGs in cancer. Our results
motivate further in vivo studies to determine the overall effects of
aHS on tumor development, and to investigate potential adverse




Mice were kept under pathogen-free conditions in the isolation
facility at the Biomedical Center, Lund University, in accordance
with the Swedish guidelines for humane treatment of laboratory
animals. The experimental setup was approved by the ethical
committee for animal research in Malmo¨/Lund, Sweden. Patient
glioblastoma samples were obtained from the Neurosurgery
Department, Lund University. Ethical permission for the present
investigation was obtained from the Lund University Regional
Ethics Board, whereby informed consent was deemed not to be
required as data were analyzed anonymously.
Materials
ScFv aHS antibodies raised against HS isolated from bovine
kidney (HS4E4), skeletal muscle from mouse (AO4B08), and
human lung (EV3C3) were used (Table 1) [26]. Mouse anti-vsv
antibody, clone p5d4, heparinase I (EC 4.2.2.7) and -III (EC
4.2.2.8) were from Sigma. Anti-integrin avb3, anti-von Willebrand
factor, and anti-a-tubulin antibodies were from Abcam, and Alexa
fluor-conjugated secondary antibodies and Phalloidin-TRITC
from Invitrogen. Anti-phospho-p38 MAPK, anti-p38 MAPK,
and anti-caspase-3 and 7 antibodies were from Cell signaling.
Human phospho-kinase and phospho-receptor tyrosine kinase
antibody array (#ARY003 and #ARY001) kits were from R&D.
P38 MAPK inhibitor (SB203580) was from Tocris, full-length
heparin and CS preparations from Sigma, and the low-molecular
weight heparin Tinzaparin from Leo Pharma. [3H]thymidine was
from Amersham, and growth factor reduced Matrigel from BD.
Fine grade chemicals and cell media supplements were from
Sigma.
Animal Xenograft Glioblastoma Tumors
Eight-week-old female NOD/SCID mice were inoculated via
s.c. injection on the dorsal region with U-87 MG cells (2.56106 in
150 ml PBS). After approximately 4 weeks of tumor growth,
animals were anesthetized with isoflurane, tumors were excised,
embedded in paraffin or OCT, and stored for further analysis.
Cell Culture
Human umbilical vein ECs (HUVECs) and human umbilical
artery ECs (HUAECs) were from Lonza. CHO-K1, CHO pgsA-
745, and U-87 MG glioblastoma cells were from the American
Type Culture Collection, and microvascular mouse ECs were
established as previously described [35]. ECs were cultured in
Endothelial basal medium (EBM), CHO cells in F12K medium
and U-87 MG cells in DMEM. Routine culture was performed in
a humidified 5% CO2 incubator at 37uC using the respective
medium supplemented with 1% l-glutamine, 100 U/ml penicillin
and 100 mg/ml streptomycin, 10% heat inactivated fetal bovine
serum (FBS) for ECs, and 10% FBS for CHO cells and U-87 MG
cells. Unless stated otherwise, experiments were performed in
medium without serum. HUVECs and HUAECs were used
Figure 3. aHS counter-acts hypoxia and starvation induced
cell-death in ECs. A, HUVECs were grown for 72 h in full medium
(10% FBS), serum free medium, or in serum free medium supplemented
with AO4B08 (aHS; 3 mg/ml), as indicated, under hypoxic conditions
(1% O2). Cell lysates were analyzed for total and cleaved caspase-3 and
7 as well as a-tubulin by immunoblotting. Upper panel shows
representative immunoblots from three independent experiments.
Lower panels show quantification of cleaved caspase/total caspase
ratios from a representative experiment. B, HUVECs were grown in
serum free medium in the absence (Ctrl) or presence of AO4B08 (aHS;
3 mg/ml) under hypoxic conditions for 72 h, and then stained with
crystal violet. Left panel shows representative images of stained cells.
Right panels shows quantitative analysis of viable cells. Data are
presented as the average6S.D. *Statistically different from untreated
Ctrl, P,0.05.
doi:10.1371/journal.pone.0049092.g003
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between passage two to six and ECs were cultured on gelatinized
cell culture plastics. For hypoxia experiments, cells were incubated
in a humidified InVivo2 Hypoxia Workstation 400 (Ruskin
Technology) set at 5% CO2, 94% N2 and 37uC.
Immunofluorescence Microscopy of Glioblastoma
Tumors
Snap frozen, human glioblastoma tumor specimens were cryo
sectioned at a thickness of 5 mm. Tumor sections were rehydrated
in PBS containing 0.05% tween-20 (PBST) for 10 min and
blocked with PBST containing 2% (w/v) BSA (BSA/PBST) for
1 h followed by incubation with c-myc tagged aHS antibody
(AO4B08, EV3C3 or HS4E4; 10 mg/ml) together with anti-
integrin avb3 antibody or anti-von Willebrand factor at 4uC
overnight. Sections were washed extensively in PBST, followed by
incubation with anti-c-myc antibody for 45 min at room
temperature. Sections were washed and incubated with goat-anti
mouse Alexa Fluor 488-conjugated antibody and goat-anti rabbit
Alexa Fluor 546-conjugated antibody for 1 h at room tempera-
ture. Control sections were stained with anti-c-myc antibody and
Alexa Fluor-conjugated antibodies in parallel. Sections were
mounted with Flourescent Mounting Medium (Dako) and were
analyzed using a Zeiss Axio Observer.Z1 HBO 100 fluorescence
microscope.
HS Lyase Digestion
For HS digestion experiments, U-87 MG mouse xenograft cryo
sections were incubated in digestion buffer (DMEM supplemented
with (25 mM Tris, 50 mM CalCl2, 50 mM NaAc, pH 8) with or
without Heparinase III (16 mIU/ml) overnight at 37uC. Sections
were rinsed extensively in PBST, and stained with aHS or 3G10
antibody as described above.
Confocal Laser Scanning Microscopy
HUVECs were cultured in eight well chamber slides and fixed
in 2% (w/v) paraformaldehyde for 5 min on ice. Cells were
blocked in PBS/BSA for 1 h followed by aHS-staining as
described. Cells were counter-stained for f-actin using Phalloi-
din-TRITC accordoing the to the instructions by the manufac-
turer. Cells were analyzed using a Zeiss LSM 710 confocal
scanning equipment with a C-Apochromate 636/1 1.2 korr W
objective and analysed with Zen software.
Cell-surface aHS Binding
For aHS binding, cells were detached with (26) PBS/0.5 mM
EDTA. Cells were then either left untreated or treated with
1.8 mU/ml heparinase III and 0.9 mIU/ml heparinase I for 2 h
in digestion buffer (DMEM supplemented with 0.5% (w/v) BSA
and 20 mM HEPES-HCl, pH 7.4), enzymes were added again for
another 2 h. aHS staining was performed essentially as described
for tumor sections; cells were extensively washed with PBS/BSA in
between antibody incubations and all incubations were performed
in PBS/BSA for 30 min on ice. aHS cell-surface binding was
analyzed by flow cytometry on a FACS Calibur instrument
integrated with CellQuest software (BD Biosciences). Control cells
without primary aHS were included in the binding experiments.
Cell Proliferation Assay
Proliferation was determined by [3H]thymidine incorporation
in serum free medium. Cells were cultured in the presence or
absence of heparin and tinzaparin for 48 h or aHS for 3 h
together with [3H]thymidine (12.5 mCi/ml), as described in the
respective Figure legend. Proliferation experiments were in some
cases performed with aHS and heparin or CS variants at the
indicated concentrations in the respective figure legend. In other
experiments, cells were pre-treated with the p38 MAPK inhibitor
SB203580 (1 mM). Cells were washed extensively with ice cold
PBS, followed by incubation with 10% (w/v) trichloric acid for
30 min on ice. Cells were washed and lysed in 0.1 M NaOH, and
an aliquot of cell lysates was neutralized with 0.1 M HCl and
analyzed for [3H]thymidine incorporation by scintillation counting
in a Beckman Coulter LS6500 Liquid Scintillation Counter. For
cell cycle phase analysis cells were treated with AO4B08 for 6 h,
detached with trypsin and washed with PBS/BSA. Cells were
pelleted, resuspended in 70% ice-cold ethanol and stored at
220uC until analyzed. Prior to analysis the samples were
resuspended in Nonidet-P40 containing 7 mg/ml Propidium
Iodide and 0.1 mg/ml RNase followed by 30 min incubation at
room temperature. Cell cycle phase was determined based on
DNA content, as analyzed by flow cytometry.
EC Elongation Assay
HUVECs were grown in the absence or presence of 3 mg/ml
aHS for 72 h. Cells were stained using crystal violet and captured
using a 46 objective (Axiovert 40C, Carl Zeiss inverted
microscope) and a digital camera to assess cell morphology. Cell
length was measured for individual cells in three microscopic fields
per well (n = 4) using Image J software (National Institutes of
Health).
Tube Formation Assay
HUVECs were seeded on growth factor reduced Matrigel at 25
000 cells/well in EBM containing 2% FBS with or without 3 mg/
ml aHS. Tubes were allowed to form over night and tubes were
captured using a 46 objective (Axiovert 40C, Carl Zeiss inverted
microscope) and a digital camera. Intact tubes were counted in
three microscopic fields per well (n = 4) using Image J software.
Figure 4. aHS stimulates the proliferation of ECs and transformed cells in an HSPG-dependent manner. A, HUVECs were grown in
serum free medium in the absence (white bars) or the presence of AO4B08 (black bars; 1.25 mg/ml) and with the indicated concentration of heparin
for 3 h and assessed for cell proliferation by the [3H]thymidine incorporation assay. *Statistically different from untreated control, P,0.05; #
Statistically different from AO4B08-treated, P,0.05. Control cells were incubated without antibody. B, HUVECs were grown in serum free medium in
the absence (white bars) or the presence of AO4B08 (black bars; 1.25 mg/ml) without (Ctrl) or with CS-6, CS4, or CS-0 (10 mg/ml), as indicated. Cell
proliferation was determined by the [3H]thymidine incorporation assay. *Statistically different from untreated control, P,0.05. C, HUVECs were grown
in serum free medium in the absence (white bars) or the presence of heparin (black bars; 10 mg/ml) without or with the different aHS antibody clones
(1.25 mg/ml), as indicated. Cell proliferation was determined by the [3H]thymidine incorporation assay. *Statistically different from untreated control,
P,0.05; # Statistically different from aHS-treated, P,0.05. D, Wild type (CHO-K1) cells and PG- deficient (PgsA-745) CHO cells were grown in serum
free medium in the absence or the presence of different aHS antibody clones (1.25 mg/ml), as indicated. Cell proliferation was determined by the
[3H]thymidine incorporation assay. *Statistically different from untreated control, P,0.05; # Statistically different from aHS-treated CHO-K1 cells,
P,0.05. E and F, Human umbilical artery ECs (HUAECs; E) and U-87 MG glioblastoma cells (F) were grown in serum free medium in the presence of
AO4B08 (aHS) at the indicated concentrations and proliferation was determined by the [3H]thymidine incorporation assay. *Statistically different from
untreated control, P,0.05.
doi:10.1371/journal.pone.0049092.g004
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Survival Assay
Cells were serum-starved and grown under hypoxic conditions
(1% O2) for 72 h with or without 3 mg/ml aHS. Cells were stained
with crystal violet and were captured using a 46 objective
(Axiovert 40C, Carl Zeiss inverted microscope) and a digital
camera. Surviving cells were counted in three microscopic fields
per well (n = 4). For immunoblot analysis, cells were seeded in 6-
well dishes and were treated as described. Cell lysate was collected
and immunoblotted for cleaved caspases-3 and 7.
Immunoblot Assay
Cells were washed in ice-cold PBS and lysed in RIPA buffer
containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM
Na2EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate,
2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, and
Complete Protease Inhibitor cocktail and phosphoSTOP (Roche
diagnostics). The lysates were centrifuged at 4500 g for 10 min and
the pellet was discarded, supernatants were measured for their
protein content using the BCATM protein assay kit (Pierce). Equal
amounts of proteins were mixed with 46 NuPage LDS sample
buffer (Invitrogen), boiled and separated by electrophoresis in a 4–
12% NuPAGE Bis-Tris gel. SeeBlue Plus2 Prestained Standard
(Invitrogen) was used as molecular mass standard. The proteins
were electroblotted to a PVDF membrane followed by blocking
with TTBS containing 5% skim milk for 1 h at room temperature
and were incubated with the indicated antibody overnight at 4uC.
Primary antibodies were complexed with HRP-conjugated
secondary IgG for 1 h at room temperature. Proteins were
visualized using ECL Western blotting substrate (Pierce) and the
membranes were exposed to X-ray film (Hyperfilm MP, Amer-
sham). Membranes were scanned and densitometry analyses were
performed using Image J software.
Phospho Kinase and Angiogenesis Arrays
HUVECs were untreated or stimulated with 1.5 mg/ml aHS for
5, 15, 45 and 60 min. Cells lysates from the different time-points
were prepared according to the kit protocol and pooled for further
analysis. Equal amounts of total protein from untreated and aHS-
treated cell lysate were analyzed for phosphorylated intracellular
and receptor tyrosine kinases using antibody arrays according to
the manufacturers instructions. For analysis of angiogenesis
Figure 5. aHS-induced proliferation of ECs and transformed
cells depends on p38 MAPK signalling activation. A, HUVECs
were incubated in serum free medium with or without aHS (AO4B08;
1.5 mg/ml) for 5, 15, 45, and 60 min, and phosphorylated receptor
tyrosine kinase proteins were determined on pooled cell lysates by
human anti-phospho receptor tyrosine kinase antibody array analysis as
described under Methods. Shown are representative immunoblots from
two independent experiments. Indicated areas show FGFR, column 1:
FGFR1; 2: FGFR2; 3: FGFR3; 4: FGFR4. PDGFR, column 1: PDGFRa; 2:
PDGFRb; 3: SCFR; 4: Flt3. VEGFR, column 1: VEGFR1; 2: VEGFR2; 3:
VEGFR3. B, HUVECs were incubated in serum free medium with or
without aHS (EV3C3; 1.5 mg/ml) for 5, 15, 45, and 60 min, and
phosphorylated kinase proteins were determined on pooled cell lysates
by human anti-phospho kinase antibody array analysis as described
under Methods. Left panels show representative immunoblots from
three independent experiments. Right panel shows quantification of p-
p38 MAPK, p-CREB, and p-ERK1/2 levels at the various conditions,
presented as relative intensities vs. array reference (red box). C, HUVECs
were either untreated (Ctrl) or incubated with aHS (AO4B08;1.25 mg/ml)
for the indicated time periods followed by immunoblotting for
phospho-p38 MAPK, total p38 MAPK and a-tubulin. Left panel shows
representative immunoblots of three separate experiments. Right panel
shows quantification of relative phospho-p38 MAPK levels (P-p38/a-
tubulin) from a representative experiment. D, Same experiment as in (C)
was performed with mouse lung microvascular ECs, showing compa-
rable induction of p38 MAPK phosphorylation by aHS as in HUVECs. E–
F, aHS-induced proliferation depends on p38 MAPK. Proliferation was
determined by [3H]thymidine incorporation in mouse ECs (E) and U-
87 MG glioblastoma cells (F) following treatment with the p38 MAPK
inhibitor SB203580 (1 mM) and/or aHS (AO4B08; 1.25 mg/ml) for 3 h, as
indicated. Basal cell proliferation was not significantly affected by p38
MAPK inhibition whereas aHS induced proliferation was almost
completely reversed. * Statistically different from untreated control,
P,0.05; # Statistically different from aHS-treated, P,0.05.
doi:10.1371/journal.pone.0049092.g005
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associated proteins, HUVECs were cultured and treated as above,
lysed with RIPA buffer supplemented with Complete protease
inhibitor cocktail, and analyzed using angiogenesis antibody array,
as recommended by the manufacturer. Array membranes were
exposed to X-ray film, scanned and protein intensities were
quantified using ImageJ software (NIH).
Statistical Analysis
Immunostaining and immunoblotting experiments are repre-
sentative of at least three experiments with similar results.
Functional data are presented as the mean6S.D. (n = 3–6).
Statistical significance was evaluated with Student’s t test using
Microsoft Excel; a P-value of ,0.05 was considered significant.
Supporting Information
Figure S1 AO4B08, EV3C3, and HS4E4 aHS clones show
positive staining in human primary ECs. A–C, Confocal
flourescence microscopy of HUVECs shows the expression of HS
epitopes recognized by the indicated aHS (green). Cells were
counter-stained for f-actin with Phalloidin-TRITC (red). D,
HUVECs were treated without (Ctrl) or with HS lyase. Cells
were surface stained at 4u with vsv-tagged AO4B08 followed by
incubation with mouse anti-vsv antibody and Alexa Fluor 488-
conjugated rabbit anti-mouse antibody. Cell surface binding of
AO4B08 was analysed using flow cytometry as described under
the Methods section, and shows HS-specific binding of the
antibody. *Statistically different from untreated control, P,0.05.
(TIF)
Figure S2 Early and sustained induction of EC prolif-
eration by aHS. HUVECs were grown in serum free medium in
the absence or presence of the indicated AO4B08 concentrations
for 3 h (white bars) or 24 h (black bars), and cell proliferation was
assessed by the [3H]thymidine incorporation assay. *Statistically
different from untreated control, P,0.05
(TIF)
Figure S3 Differential binding of AO4B08, EV3C3, and
HS4E4 aHS clones to ECs. A, HUVECs were detached by
concentrated PBS (x2)/EDTA and surface stained at 4u with
AO4B08, EV3C3, or HS4E4 aHS clones (10 mg/ml). aHS cell-
surface binding was analysed by flow cytometry. B, HUVECs
were surface stained at 4u with mouse anti-vsv antibody and Alexa
Fluor 488-conjugated rabbit anti-mouse antibody (Ctrl, white
area), or with vsv-tagged AO4B08, mouse anti-vsv antibody, and
Alexa Fluor 488-conjugated rabbit anti-mouse antibody in the
absence (black area) or in the presence of heparin (10 mg/ml; grey
area). Cell surface binding was analysed using flow cytometry.
Right panel: Data are presented as the average6S.D.
(TIF)
Figure S4 aHS induces P38 MAPK activation in U-
87 MG cells and aHS-mediated signalling is blocked by
P38 MAPK inhibition. A, U-87 MG glioblastoma cells were
either untreated (Ctrl) or incubated with aHS (AO4B08; 1.25 mg/
ml) for the indicated time periods followed by immunoblotting for
phospho-p38 MAPK and a-tubulin. Left panel shows represen-
tative immunoblots of three separate experiments. Right panel
shows quantification of relative phospho-p38 MAPK levels (p-
p38/a-tubulin) from a representative experiment. B, Same
experiment as in (A) was performed with HUVECs, either
untreated (Ctrl) or treated with aHS (AO4B08; 1.25 mg/ml) for
the indicated time periods with or without 30 min pre-treatment
with p38 MAPK inhibitor SB203580 (2 mM) as indicated. Left
panel shows representative immunoblots of three separate
experiments. Right panel shows quantification of relative phos-
pho-p38 MAPK levels (p-p38/a-tubulin) from a representative
experiment. C, HUVECs were left untreated or pre-treated with
p38 MAPK inhibitor SB203580 (2 mM) for 30 min, stimulated
with FBS (10%) or aHS (AO4B08; 1.25 mg/ml), followed by
immunoblotting for phospho-CREB, total CREB, and a-tubulin.
Left panel shows representative immunoblots of three separate
experiments. Right panel shows quantification of relative phospho-
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